Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Biotechnologie”

13:00 · DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference · Persbericht

13:00 · DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference · Persbericht

13:00 · Evogene to Present Its Pharma Division Achievements at the BIO International Convention · Persbericht

13:00 · RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation · Persbericht

04:22 · IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants · Persbericht

03:23 · Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq · Persbericht

8/06 · DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 · Persbericht

8/06 · Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients · Persbericht

8/06 · Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer · Persbericht

8/06 · Lakefront benoemt dr. Eric Hedrick tot Chief Medical Officer · Persbericht

8/06 · IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants · Persbericht

8/06 · GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH · Persbericht

8/06 · Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution · Persbericht

8/06 · Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities · Persbericht

8/06 · Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine · Persbericht

8/06 · Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development · Persbericht

8/06 · RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo · Persbericht

8/06 · Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 · Persbericht

7/06 · AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS · Persbericht

5/06 · DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference · Persbericht

5/06 · Voting Rights and Shares Capital of the Company · Persbericht

Mijn selecties